NASDAQ:GWPH - GW Pharmaceuticals PLC- Stock Price, Forecast & News

GW Pharmaceuticals PLC- trades on the NASDAQ under the ticker symbol "GWPH."

GW Pharmaceuticals PLC- (NASDAQ:GWPH) issued its quarterly earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($0.48) EPS for the quarter, beating the Zacks' consensus estimate of ($0.87) by $0.39. The biopharmaceutical company had revenue of $90.97 million for the quarter, compared to analysts' expectations of $86.84 million. GW Pharmaceuticals PLC- had a negative net margin of 26.80% and a negative return on equity of 23.04%. View GW Pharmaceuticals PLC-'s Earnings History.

GW Pharmaceuticals PLC- is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for GW Pharmaceuticals PLC-.

12 Wall Street analysts have issued 12-month price objectives for GW Pharmaceuticals PLC-'s stock. Their forecasts range from $134.00 to $238.00. On average, they expect GW Pharmaceuticals PLC-'s share price to reach $198.80 in the next twelve months. This suggests a possible upside of 67.1% from the stock's current price. View Analyst Price Targets for GW Pharmaceuticals PLC-.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GW Pharmaceuticals PLC- in the last year. There are currently 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GW Pharmaceuticals PLC-.

Media headlines about GWPH stock have been trending very negative recently, InfoTrie reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. GW Pharmaceuticals PLC- earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for GW Pharmaceuticals PLC-.

GW Pharmaceuticals PLC- saw a increase in short interest in the month of December. As of December 13th, there was short interest totalling 5,760,000 shares, an increase of 5.5% from the November 28th total of 5,460,000 shares. Based on an average daily volume of 783,300 shares, the days-to-cover ratio is presently 7.4 days. Currently, 18.8% of the company's shares are short sold. View GW Pharmaceuticals PLC-'s Current Options Chain.

Some companies that are related to GW Pharmaceuticals PLC- include Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Teva Pharmaceutical Industries (TEVA), Elanco Animal Health (ELAN), Mylan (MYL), Bausch Health Companies (BHC), Beigene (BGNE), Sarepta Therapeutics (SRPT), Ono Pharmaceutical (OPHLF), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO) and Horizon Therapeutics (HZNP).

Based on aggregate information from My MarketBeat watchlists, some companies that other GW Pharmaceuticals PLC- investors own include Canopy Growth (CGC), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), Aurora Cannabis (ACB), Cronos Group (CRON), Tesla (TSLA), GW Pharmaceuticals (GWP) and Tilray (TLRY).

GW Pharmaceuticals PLC-'s stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Independent Investors Inc. (0.03%), Wedbush Securities Inc. (0.01%), Steward Partners Investment Advisory LLC (0.00%) and Horrell Capital Management Inc. (0.00%). Company insiders that own GW Pharmaceuticals PLC- stock include Adam D George, Cabot Brown, Catherine J Mackey, Christopher J Tovey, Douglas B Snyder, Geoffrey W Dr Guy, James Noble, Julian S Gangolli, Justin D Gover, Scott M Giacobello, Volker Knappertz and William A Waldegrave. View Institutional Ownership Trends for GW Pharmaceuticals PLC-.

GWPH stock was sold by a variety of institutional investors in the last quarter, including Steward Partners Investment Advisory LLC and Horrell Capital Management Inc.. Company insiders that have sold GW Pharmaceuticals PLC- company stock in the last year include Adam D George, Cabot Brown, Catherine J Mackey, Christopher J Tovey, Douglas B Snyder, Geoffrey W Dr Guy, James Noble, Julian S Gangolli, Justin D Gover, Scott M Giacobello, Volker Knappertz and William A Waldegrave. View Insider Buying and Selling for GW Pharmaceuticals PLC-.

GWPH stock was bought by a variety of institutional investors in the last quarter, including Independent Investors Inc. and Wedbush Securities Inc.. View Insider Buying and Selling for GW Pharmaceuticals PLC-.

Shares of GWPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GWPH stock can currently be purchased for approximately $118.97.

GW Pharmaceuticals PLC- has a market capitalization of $3.67 billion and generates $12.74 million in revenue each year. The biopharmaceutical company earns $-79,880,000.00 in net income (profit) each year or ($10.56) on an earnings per share basis. GW Pharmaceuticals PLC- employs 791 workers across the globe.View Additional Information About GW Pharmaceuticals PLC-.

The official website for GW Pharmaceuticals PLC- is http://www.gwpharm.com/.

GW Pharmaceuticals PLC-'s mailing address is SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ. The biopharmaceutical company can be reached via phone at 44-12-2326-6800 or via email at [email protected]